ReviewClinical & translational immunology2018
Vaccinating for natural killer cell effector functions.
Review in Clinical & translational immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Integrated reiterative pipeline for rapid epitope-based pan-alphavirus vaccines.Science advances · 2026Article
- Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy.Frontiers in immunology · 2026Article
- Ad5-boosted COVID-19 vaccine reduces symptomatic BA.5 infection via cross-neutralizing antibodies and NK cell immunity.BMC medicine · 2025Article
- Correlation between IL-18 secretion by peripheral blood mononuclear cells and NK cells activation after SARS-CoV-2 booster vaccination in HIV-1-infected individuals.Infectious diseases & immunity · 2025Article
- Interplay between innate immune cells and inflammatory mediators in dengue infection: an evolving therapeutic paradigm.Expert reviews in molecular medicine · 2025Review
- NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.Molecular medicine (Cambridge, Mass.) · 2022Article
- Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination.Frontiers in immunology · 2022Article
- Immunological Analysis of Nodavirus Capsid Displaying the Domain III of Japanese Encephalitis Virus Envelope Protein.Pharmaceutics · 2021Article
- Targeting natural killer cells to enhance vaccine responses.Trends in pharmacological sciences · 2021Review
- The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency.Frontiers in immunology · 2021Article
- New horizons for natural killer cell research in cancer, infection and inflammation.Clinical & translational immunology · 2021Article
- Precision Vaccine Development: Cues From Natural Immunity.Frontiers in immunology · 2021Review
- Vaccine responses in ageing and chronic viral infection.Oxford open immunology · 2021Review
- Protective Vaccination Reshapes Hepatic Response to Blood-Stage Malaria of Genes Preferentially Expressed by NK Cells.Vaccines · 2020Article
- Considerations of Antibody Geometric Constraints on NK Cell Antibody Dependent Cellular Cytotoxicity.Frontiers in immunology · 2020Review
- Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure.Mediterranean journal of hematology and infectious diseases · 2020Article
- Live Vaccines Have Different NK Cells and Neutrophils Requirements for the Development of a Protective Immune Response Against Tuberculosis.Frontiers in immunology · 2020Article
- Natural Killer Cells Dampen the Pathogenic Features of Recall Responses to Influenza Infection.Frontiers in immunology · 2020Article
- Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Vaccination has proved to be highly effective in reducing global mortality and eliminating infectious diseases. Building on this success will depend on the development of new and improved vaccines, new methods to determine efficacy and optimum dosing and new or refined adjuvant systems. NK cells are innate lymphoid cells that respond rapidly during primary infection but also have adaptive characteristics enabling them to integrate innate and acquired immune responses. NK cells are activated after vaccination against pathogens including influenza, yellow fever and tuberculosis, and their subsequent maturation, proliferation and effector function is dependent on myeloid accessory cell-derived cytokines such as IL-12, IL-18 and type I interferons. Activation of antigen-presenting cells by live attenuated or whole inactivated vaccines, or by the use of adjuvants, leads to enhanced and sustained NK cell activity, which in turn contributes to T cell recruitment and memory cell formation. This review explores the role of cytokine-activated NK cells as vaccine-induced effector cells and in recall responses and their potential contribution to vaccine and adjuvant development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.